Thrombin-activatable fibrinolysis inhibitor is activated in vivo in a baboon model of Escherichia coli induced sepsis

Journal of Thrombosis and Thrombolysis

Volumn 33, Issue 4, 2012, Pages 412-415

  Kim, Paul Y ^a,b   Kim, Paula Y G ^c   Taylor, Fletcher B ^d   Nesheim, Michael E ^c,d  

^a MCMASTER UNIVERSITY   (Canada)

^b David Braley Cardiac Vascular and Stroke Research Institute   (Canada)

^c QUEEN S UNIVERSITY   (Canada)

^d OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

Activated thrombin activatable fibrinolysis inhibitor (TAFIa); Baboon; CPU; In vivo; Sepsis

Indexed keywords

FIBRIN DEGRADATION PRODUCT; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BABOON; CATALYSIS; COLONY FORMING UNIT; CONTROLLED STUDY; COVALENT BOND; ENZYME ACTIVATION; ENZYME ASSAY; ENZYME BLOOD LEVEL; ESCHERICHIA COLI INFECTION; FLUORESCENCE ANALYSIS; IN VIVO STUDY; LETHAL DOSE; NONHUMAN; PRIORITY JOURNAL; PROCESS DEVELOPMENT; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; SEPSIS; ANIMAL; BLOOD; DISEASE MODEL; ESCHERICHIA COLI; MALE; MICROBIOLOGY; PAPIO CYNOCEPHALUS; TIME;

ANIMALS; CARBOXYPEPTIDASE U; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; MALE; PAPIO CYNOCEPHALUS; SEPSIS; TIME FACTORS;

EID: 84865145520     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-011-0676-4     Document Type: Article

References (19)

1. Nesheim M, Wang W, Boffa M, Nagashima M, Morser J, Bajzar L (1997) Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost 78:386-391
2. Bouma BN, Marx PF, Mosnier LO, Meijers JCM (2001) Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). Thromb Res 101(5):329-354
3. Willemse JL, Hendriks DF (2007) A role for procarboxypepidase U (TAFI) in thrombosis. Front Biosci 12:1973-1987
4. Bajzar L (2000) Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler Thromb Vasc Biol 20(12):2511-2518
5. Bajzar L, Morser J, Nesheim M (1996) TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 271:16603-16608
6. Heylen E, Van Goethem S, Augustyns K, Hendriks D (2010) Measurement of carboxypeptidase U (active thrombin-activatable fibrinolysis inhibitor) in plasma: challenges overcome by a novel selective assay. Anal Biochem 403(1-2):114-116
7. Willemse JL, Hendriks DF (2006) Measurement of procarboxypeptidase U (TAFI) in human plasma: a laboratory challenge. Clin Chem 52(1):30-36
8. Kim PY, Foley J, Hsu G, Kim PY, Nesheim ME (2008) An assay for measuring functional activated thrombin-activatable fibrinolysis inhibitor in plasma. Anal Biochem 372(1):32-40
9. Heylen E, Van Goethem S, Willemse J, Olsson T, Augustyns K, Hendriks D (2010) Development of a sensitive and selective assay for the determination of procarboxypeptidase U (thrombinactivatable fibrinolysis inhibitor) in plasma. Anal Biochem 396(1):152-154
10. Willemse JL, Brouns R, Heylen E, De Deyn PP, Hendriks DF (2008) Carboxypeptidase U (TAFIa) activity is induced in vivo in ischemic stroke patients receiving thrombolytic therapy. J Thromb Haemost 6(1):200-202
11. Kim PY, Kim PY, Hoogendorn H, Giles AR, Nesheim ME (2008) Activated thrombin-activatable fibrinolysis inhibitor is generated in vivo at levels that can substantially affect fibrinolysis in chimpanzees in response to thrombin generation. J Thromb Haemost 6(9):1600-1602
12. Taylor FB, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE (1987) Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 79:918-925
13. Taylor FB Jr. (2001) Staging of the pathophysiologic responses of the primate microvasculature to Escherichia coli and endotoxin: examination of the elements of the compensated response and their links to the corresponding uncompensated lethal variants. Crit Care Med 29(7 Suppl):S78-S89
14. Binette TM, Taylor FB Jr., Peer G, Bajzar L (2007) Thrombinthrombomodulin connects coagulation and fibrinolysis: more than an in vitro phenomenon. Blood 110(9):3168-3175
15. Boffa MB, Wang W, Bajzar L, Nesheim ME (1998) Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/ thrombomodulin-dependent activation, thermal stability, and enzymatic properties. J Biol Chem 273(4):2127-2135
16. Schneider M, Boffa M, Stewart R, Rahman M, Koschinsky M, Nesheim M (2002) Two naturally occurring variants of TAFI (Thr-325 and Il-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J Biol Chem 277(2):1021-1030
17. Bajzar L, Jain N, Wang P, Walker JB (2004) Thrombin activatable fibrinolysis inhibitor: not just an inhibitor of fibrinolysis. Crit Care Med 32(5 Suppl):S320-S324
18. Song JJ, Hwang I, Cho KH, Garcia MA, Kim AJ, Wang TH, Lindstrom TM, Lee AT, Nishimura T, Zhao L, Morser J, Nesheim M, Goodman SB, Lee DM, Bridges SL Jr., Gregersen PK, Leung LL, Robinson WH (2011) Plasma carboxypeptidase B downregulates inflammatory responses in autoimmune arthritis. J Clin Invest 121(9):3517-3527
19. Zeerleder S, Schroeder V, Hack E, Kohler HP, Wuillemin WA (2006) TAFI and PAI-1 levels in human sepsis. Thromb Res 118(2):205-212